Published in

Wiley, Journal of Paediatrics and Child Health, 1(58), p. 46-53, 2021

DOI: 10.1111/jpc.15811

Links

Tools

Export citation

Search in Google Scholar

COVID‐19 in children. II: Pathogenesis, disease spectrum and management

Journal article published in 2021 by Annaleise R. Howard‐Jones ORCID, David P. Burgner ORCID, Nigel W. Crawford, Emma Goeman, Paul E. Gray, Peter Hsu, Stephanie Kuek, Brendan J. McMullan ORCID, Shidan Tosif ORCID, Danielle Wurzel, Asha C. Bowen, Margie Danchin ORCID, Archana Koirala ORCID, Ketaki Sharma, Daniel K. Yeoh ORCID and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The global disruption of the COVID‐19 pandemic has impacted the life of every child either directly or indirectly. This review explores the pathophysiology, immune response, clinical presentation and treatment of COVID‐19 in children, summarising the most up‐to‐date data including recent developments regarding variants of concern. The acute infection with SARS‐CoV‐2 is generally mild in children, whilst the post‐infectious manifestations, including paediatric inflammatory multisystem syndrome temporally associated with SARS‐CoV‐2 (PIMS‐TS) and ‘long COVID’ in children, are more complex. Given that most research on COVID‐19 has focused on adult cohorts and that clinical manifestations, treatment availability and impacts differ markedly in children, research that specifically examines COVID‐19 in children needs to be prioritised.